{
  "docId": "019dd923-622c-750b-8b9b-7e7228555e88",
  "docSlug": "36c903ba19aa",
  "documentTitle": "Allergan, Inc. (AGN)",
  "authorId": "01_Pershing_Square",
  "authorName": "William Ackman",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2014-04-22 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.70665085,
  "pageNumber": 11,
  "pageCount": 110,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "before_after",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The chart highlights the correlation between CEO tenure/acquisitions and stock performance.",
  "elementsJson": [
    "headline_text",
    "callout_box",
    "line_chart",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9b-7e7228555e88/11",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.1,
        "x": 0.7,
        "y": 0.22
      },
      "kind": "callout",
      "text": "5/27/13: Announced acquisition of Bausch & Lomb for $8.7bn",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00f1f661-21cf-4b86-8b51-aa7c49e19342",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.1,
        "x": 0.19,
        "y": 0.35
      },
      "kind": "callout",
      "text": "2/1/08: Mike Pearson appointed CEO; Valeant share",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03af30ef-6646-47d0-bdb5-e1c2f76a064c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.1,
        "x": 0.6,
        "y": 0.3
      },
      "kind": "callout",
      "text": "9/3/12: Announced acquisition of Medicis for $2.6bn",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3d05888-e670-4497-98b7-7c2da9b9d05b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.1,
        "x": 0.37,
        "y": 0.34
      },
      "kind": "callout",
      "text": "6/20/10: Announced merger with Biovail",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e57541b1-022f-43eb-aa58-c29ea662ad12",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "An investment in Valeant shares on the day Mike Pearson became CEO has appreciated 25x in six years including dividend reinvestment",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-f5d3-71df-9940-b1a9ef30e38a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.82,
        "x": 0.09,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Valeant total shareholder return from 2/1/2008 to 4/21/2014",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65b40367-c8b4-4e32-b4aa-a81e53de06b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.82,
        "x": 0.09,
        "y": 0.75
      },
      "kind": "disclaimer",
      "text": "Note: Chart shows the total shareholder return for an investment in Valeant Pharmaceuticals International...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c49875df-a862-45b2-bc6f-ad5f04952ca1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Total Shareholder Return: 2,544%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-f5d3-71df-9940-b6002f95914e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.82,
        "x": 0.09,
        "y": 0.13
      },
      "kind": "title",
      "text": "An investment in Valeant shares on the day Mike Pearson became CEO has appreciated 25x in six years including dividend reinvestment",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c62057d-12f4-4ba5-ba9b-4ce0241916d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.82,
        "x": 0.09,
        "y": 0.1
      },
      "kind": "title",
      "text": "Valeant TSR Under Mike Pearson's Leadership",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66da8109-a8d5-4fe4-b970-e308e5cc413d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "20c18ddc-81f5-4745-b8fd-aaa535de2407",
      "evidence": "An investment in Valeant shares on the day Mike Pearson became CEO has appreciated 25x in six years including dividend reinvestment",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "d87c542b-fa40-4967-aee3-48b500f948c4",
      "evidence": "Shows performance before and after CEO appointment and specific acquisitions.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 11,
      "name": "Tale Two Worlds",
      "slug": "04-tale-two-worlds",
      "bestFor": "Competitive analysis, benchmarking, case for change",
      "matchId": "ca42c337-96bb-4b04-8fe1-99f0e68466ed",
      "evidence": "The presentation uses data and charts to compare Valeant's performance with that of its peers",
      "position": 0,
      "objective": "To contrast Valeant's performance with that of traditional pharmaceutical companies",
      "structure": "Current State -> Desired State / Benchmark -> The Gap & Implication",
      "confidence": 0.7,
      "description": "Show the gap between two states to drive urgency or highlight opportunity"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}